Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024)

Avalo Therapeutics' Gross Margin history spans 8 years, with the latest figure at 186.75% for Q3 2024.

  • For Q3 2024, Gross Margin fell 18209.0% year-over-year to 186.75%; the TTM value through Sep 2024 reached 11.71%, down 1722.0%, while the annual FY2023 figure was 33.26%, 4771.0% down from the prior year.
  • Gross Margin reached 186.75% in Q3 2024 per AVTX's latest filing, down from 138.7% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 138.7% in Q4 2023 to a low of 186.75% in Q3 2024.
  • Average Gross Margin over 5 years is 23.2%, with a median of 32.74% recorded in 2021.
  • Peak YoY movement for Gross Margin: tumbled -18833bps in 2021, then skyrocketed 12441bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 94.72% in 2020, then tumbled by -199bps to 93.61% in 2021, then soared by 133bps to 30.8% in 2022, then surged by 350bps to 138.7% in 2023, then crashed by -235bps to 186.75% in 2024.
  • Per Business Quant, the three most recent readings for AVTX's Gross Margin are 186.75% (Q3 2024), 138.7% (Q4 2023), and 4.66% (Q3 2023).